MagIA Diagnostics

MagIA develops an innovative blood immunoanalyzer allowing for easy transfer of any immunoassay onto a portable system, with lab performance. 
MagIA delivers his partner’s immunoassays directly to patients through our proprietary Point of Care device. 

The growing challenges of personalised medicine and pandemic management drive the need for Point of Care solutions pushing diagnostic companies (10 B$ CAGR) to bring their assays closer to the patient. However, developping efficient Point-of-Care immunodiagnostic solutions that are both affordable and accurate, remains the major issue for diagnostic companies and healthcare labs on Point of Care devices.

MAGIA has developped a patented Point of Care immunodiagnostic solution comprising a small reader (20x20cm) and disposable cartridge, easy to use, on which existing immunoassay can be rapidly transferred. This novel technology exhibits lab performance, and better in some cases. Within a co-development framework with immunodiagnostic & pharma companies, MAGIA transfers, validates and produces their lab immunoassay on its proprietary cartridge.

MAGIA target Point of Care immunoassay market (Global Revenue >1B$), mainly localized in Europe and the US (70%), which is split into 2 segments : Emergency (Cardiac Markers, Sepsis) and infectious disease screening.